Boston Scientific Corp
NYSE:BSX

Watchlist Manager
Boston Scientific Corp Logo
Boston Scientific Corp
NYSE:BSX
Watchlist
Price: 92.7 USD 0.18% Market Closed
Market Cap: 137.4B USD

Intrinsic Value

The intrinsic value of one BSX stock under the Base Case scenario is 77.27 USD. Compared to the current market price of 92.7 USD, Boston Scientific Corp is Overvalued by 17%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BSX Intrinsic Value
77.27 USD
Overvaluation 17%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Boston Scientific Corp

What is Valuation History?
Ask AI Assistant
What other research platforms think about BSX?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is BSX valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Boston Scientific Corp.

Explain Valuation
Compare BSX to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Boston Scientific’s heavy reliance on continually launching breakthrough products leaves it exposed to costly recalls and regulatory delays, particularly for critical new cardiac devices and implantables. Even small disruptions could jeopardize revenue momentum and compromise trust with healthcare providers.

Having pursued a number of acquisitions in recent years, Boston Scientific faces execution risks in integrating these deals. If the company struggles to realize synergies or manage overlapping product lines, it could distract from core R&D and reduce the return on investment.

Persistent pricing pressure and reimbursement challenges in established markets, especially in interventional cardiology and endoscopy, could weigh on profitability. As rivals introduce more aggressive pricing strategies and governments tighten healthcare budgets, margins may be squeezed.

Bull Theses

A robust product pipeline—led by next-generation Watchman devices, advanced neuromodulation systems, and emerging interventional solutions—positions Boston Scientific to sustain above-average growth in procedural areas with expanding patient populations.

Its strong foothold in key therapeutic categories, including cardiovascular and structural heart interventions, has forged deep relationships with hospitals and clinicians. This entrenched customer base could provide a reliable platform for launching innovative products and capturing share in growth segments.

Geographic expansion and investments in higher-growth emerging markets add important diversification to Boston Scientific’s revenue streams, enhancing its ability to offset slower demand in mature markets and reduce exposure to any single region’s economic cycles.

Show More Less
How do you feel about BSX?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Boston Scientific Corp

Current Assets 8B
Cash & Short-Term Investments 1.3B
Receivables 2.8B
Other Current Assets 3.9B
Non-Current Assets 34.7B
Long-Term Investments 643m
PP&E 4.3B
Intangibles 25.4B
Other Non-Current Assets 4.4B
Current Liabilities 5.3B
Accounts Payable 1B
Accrued Liabilities 2.8B
Other Current Liabilities 1.5B
Non-Current Liabilities 14B
Long-Term Debt 11.1B
Other Non-Current Liabilities 2.9B
Efficiency

Free Cash Flow Analysis
Boston Scientific Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Boston Scientific Corp

Revenue
19.4B USD
Cost of Revenue
-6.1B USD
Gross Profit
13.3B USD
Operating Expenses
-9.5B USD
Operating Income
3.8B USD
Other Expenses
-963m USD
Net Income
2.8B USD
Fundamental Scores

BSX Profitability Score
Profitability Due Diligence

Boston Scientific Corp's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin
Strong 3Y Average Gross Margin
ROE is Increasing
Healthy Operating Margin
54/100
Profitability
Score

Boston Scientific Corp's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

BSX Solvency Score
Solvency Due Diligence

Boston Scientific Corp's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Long-Term Solvency
High Interest Coverage
64/100
Solvency
Score

Boston Scientific Corp's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BSX Price Targets Summary
Boston Scientific Corp

Wall Street analysts forecast BSX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BSX is 128.25 USD with a low forecast of 102.46 USD and a high forecast of 147 USD.

Lowest
Price Target
102.46 USD
11% Upside
Average
Price Target
128.25 USD
38% Upside
Highest
Price Target
147 USD
59% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Boston Scientific Corp
does not pay dividends
Shareholder Yield

Current shareholder yield for BSX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

BSX Insider Trading
Buy and sell transactions by insiders

BSX News

Other Videos
What is the Intrinsic Value of one BSX stock?

The intrinsic value of one BSX stock under the Base Case scenario is 77.27 USD.

Is BSX stock undervalued or overvalued?

Compared to the current market price of 92.7 USD, Boston Scientific Corp is Overvalued by 17%.

Back to Top